Navigation Links
Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
Date:3/17/2010

SAN DIEGO, March 17 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.  Hydrocodone is the most widely prescribed drug in the United States, but there are currently no products available with hydrocodone only, or with controlled-release formulations.  ZX002, which incorporates Elan's proprietary SODAS® technology, offers a unique controlled-release profile which utilizes both immediate release and extended release properties designed to enable twice daily dosing.

"We are pleased to be initiating this pivotal Phase 3 trial of ZX002 as the first single-entity, controlled-release hydrocodone formulation," said Cynthia Robinson, Ph.D., chief development officer of Zogenix.  "We believe this hydrocodone therapy could offer significant benefits to both the patient and the practicing physician by allowing for less frequent dosing with a customized controlled-release profile and the ability to titrate to higher hydrocodone doses than currently recommended for hydrocodone products burdened by combination formulations. Further, we believe ZX002 may offer patients an option for the treatment of their chronic pain that potentially avoids some of the serious side effects that can accompany chronic use of combination opioids that contain acetaminophen, or other n
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
2. ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
3. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
4. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
5. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
6. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
7. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
8. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
9. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
10. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
11. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "North American Active Wound ... Application (Surgical Wound, & Ulcer), by End-User (In-Patient, ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... is estimated to grow at a CAGR of ...
(Date:5/21/2015)... Mass. , May 21, 2015  (MUSE ... the Electronic Health Record (EHR) is invaluable in ... Though EHRs are now a requirement and mainstream ... and continuously into the EHR is gaining traction ... Exchange), William Holmes, RN, Site Project Manager & ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... 2011 /PRNewswire-iReach/ -- UBM Medica today announced ... features content dedicated to the latest developments in the ... other major rheumatologic diseases. (Photo:   http://photos.prnewswire.com/prnh/20111026/CG93984 ... have altered the landscape of rheumatology and the quality ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2UBM Medica's Musculoskeletal Network Highlights Changing Rheumatologic Landscape 2UBM Medica's Musculoskeletal Network Highlights Changing Rheumatologic Landscape 3
(Date:5/22/2015)... (PRWEB) May 22, 2015 Hundreds ... on behalf of individuals who allegedly experienced serious ... use continue to move forward in the U.S. ... a Pretrial Order dated May 4, 2015, the ... documents and electronically stored information. Among other things, ...
(Date:5/22/2015)... 2015 “It’s like learning an ... CHHRP-QT, Vice President of Clinical Operations/Education and Training ... that impacts how care is coded and reimbursed.” ... term care reimbursement, operations and compliance consulting, as ... management, launches a new series of day-long seminars ...
(Date:5/22/2015)... According to a new Aegis Living Study on Attitudes ... to worry about what will happen to their memory as ... Silent Generation), which may help explain why nearly half of ... Millennials (47%), Gen X’ers (51%), and Boomers (43%). The study ... more than 2,000 U.S. adults ages 18+. , “This ...
(Date:5/22/2015)... May 22, 2015 The ... Dental announces that they are now offering complimentary ... other dental treatments. At consultations, patients can discuss ... regarding what certain treatments can achieve and whether ... during this initial appointment. If treatments are chosen, ...
(Date:5/22/2015)... FL (PRWEB) May 22, 2015 Wimbledon ... provides vascular, electrocardiogram (EKG), echocardiogram and NCV testing ... Sempier, a highly respected All American National athlete, to ... athlete, I find the high level of testing and ... the athlete and their athletic trainers, this way they ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3
... of supplemental zinc is associated with an increased risk ... data from the Health Professionals Follow-up Study. ,The prostate ... tissues. However, studies of the effect of zinc on ... men followed in the health professionals study, there were ...
... monitoring will be to health care what the compound ... body monitoring,is a simple device worn on the body, ... a number of physiological levels.,This includes time spent lying ... temperature, calories burned, and more. ,Few medical advances ...
... apnea, a sleep disorder that causes people to temporarily stop ... bed-wetting in children, said Dr. Lee J. Brooks, a clinical ... Philadelphia. ,In a study of 160 kids ages 4 ... suspected breathing problems at night, 66 children (41 percent) were ...
... uses a neat trick to repair its most crucial genes, ... over evolutionary time. ,The Y chromosome, of course, is best ... than females. ,Some scientists have suggested it might disappear ... defects in the usual way,// and broken genes tend to ...
... be preventing a fatal traffic accident -- at least in ... traffic convictions on the likelihood of being involved in a ... risk of getting in a fatal crash in the month ... no conviction took place., ,About 1 million people die in ...
... bitten by animals poses little problem for doctors, but what ... the question researchers set out to answer in a new ... Surgery. Their review of 10 years worth of hospital records ... form a standard protocol to follow when man bites man. ...
Cached Medicine News:Health News:Sleep Apnea Linked to Bed-Wetting in Kids 2Health News:Y chromosome uses trick to repair its own genes 2
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce large devices for vascular intervention....
Used to introduce large devices for vascular intervention....
Medicine Products: